Header Logo

Connection

Douglas Golenbock to Membrane Glycoproteins

This is a "connection" page, showing publications Douglas Golenbock has written about Membrane Glycoproteins.
Connection Strength

7.587
  1. Nagpal K, Plantinga TS, Wong J, Monks BG, Gay NJ, Netea MG, Fitzgerald KA, Golenbock DT. A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J Biol Chem. 2009 Sep 18; 284(38):25742-8.
    View in: PubMed
    Score: 0.257
  2. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 2005 Apr 29; 280(17):17005-12.
    View in: PubMed
    Score: 0.190
  3. Golenbock DT. Introduction: Toll receptors come of age. Microbes Infect. 2004 Dec; 6(15):1349-50.
    View in: PubMed
    Score: 0.188
  4. Fitzgerald KA, Rowe DC, Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect. 2004 Dec; 6(15):1361-7.
    View in: PubMed
    Score: 0.188
  5. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004 Feb; 5(2):190-8.
    View in: PubMed
    Score: 0.177
  6. Latz E, Visintin A, Espevik T, Golenbock DT. Mechanisms of TLR9 activation. J Endotoxin Res. 2004; 10(6):406-12.
    View in: PubMed
    Score: 0.176
  7. Lien E, Golenbock DT. Adjuvants and their signaling pathways: beyond TLRs. Nat Immunol. 2003 Dec; 4(12):1162-4.
    View in: PubMed
    Score: 0.175
  8. Latz E, Golenbock DT. Receptor "cross talk" in innate immunity. J Clin Invest. 2003 Oct; 112(8):1136-7.
    View in: PubMed
    Score: 0.173
  9. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, Golenbock DT. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med. 2003 Oct 06; 198(7):1043-55.
    View in: PubMed
    Score: 0.173
  10. Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem. 2003 Nov 28; 278(48):48313-20.
    View in: PubMed
    Score: 0.172
  11. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1966-71.
    View in: PubMed
    Score: 0.165
  12. Espevik T, Latz E, Lien E, Monks B, Golenbock DT. Cell distributions and functions of Toll-like receptor 4 studied by fluorescent gene constructs. Scand J Infect Dis. 2003; 35(9):660-4.
    View in: PubMed
    Score: 0.164
  13. Fierer J, Swancutt MA, Heumann D, Golenbock D. The role of lipopolysaccharide binding protein in resistance to Salmonella infections in mice. J Immunol. 2002 Jun 15; 168(12):6396-403.
    View in: PubMed
    Score: 0.158
  14. Henneke P, Golenbock DT. Innate immune recognition of lipopolysaccharide by endothelial cells. Crit Care Med. 2002 May; 30(5 Suppl):S207-13.
    View in: PubMed
    Score: 0.157
  15. Henneke P, Takeuchi O, van Strijp JA, Guttormsen HK, Smith JA, Schromm AB, Espevik TA, Akira S, Nizet V, Kasper DL, Golenbock DT. Novel engagement of CD14 and multiple toll-like receptors by group B streptococci. J Immunol. 2001 Dec 15; 167(12):7069-76.
    View in: PubMed
    Score: 0.153
  16. Henneke P, Golenbock DT. TIRAP: how Toll receptors fraternize. Nat Immunol. 2001 Sep; 2(9):828-30.
    View in: PubMed
    Score: 0.150
  17. Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, Heine H, Latz E, Monks BG, Schwartz DA, Miyake K, Golenbock DT. Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med. 2001 Jul 02; 194(1):79-88.
    View in: PubMed
    Score: 0.148
  18. Ingalls RR, Lien E, Golenbock DT. Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through toll-like receptor 2. Infect Immun. 2001 Apr; 69(4):2230-6.
    View in: PubMed
    Score: 0.146
  19. Golenbock DT, Fenton MJ. Extolling the diversity of bacterial endotoxins. Nat Immunol. 2001 Apr; 2(4):286-8.
    View in: PubMed
    Score: 0.146
  20. Lien E, Chow JC, Hawkins LD, McGuinness PD, Miyake K, Espevik T, Gusovsky F, Golenbock DT. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway. J Biol Chem. 2001 Jan 19; 276(3):1873-80.
    View in: PubMed
    Score: 0.141
  21. Dembny P, Newman AG, Singh M, Hinz M, Szczepek M, Kr?ger C, Adalbert R, Dzaye O, Trimbuch T, Wallach T, Kleinau G, Derkow K, Richard BC, Schipke C, Scheidereit C, Stachelscheid H, Golenbock D, Peters O, Coleman M, Heppner FL, Scheerer P, Tarabykin V, Ruprecht K, Izsv?k Z, Mayer J, Lehnardt S. Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors. JCI Insight. 2020 04 09; 5(7).
    View in: PubMed
    Score: 0.136
  22. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest. 2000 Feb; 105(4):497-504.
    View in: PubMed
    Score: 0.134
  23. Ingalls RR, Lien E, Golenbock DT. Differential roles of TLR2 and TLR4 in the host response to Gram-negative bacteria: lessons from a lipopolysaccharide-deficient mutant of Neisseria meningitidis. J Endotoxin Res. 2000; 6(5):411-5.
    View in: PubMed
    Score: 0.134
  24. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls RR, Radolf JD, Golenbock DT. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem. 1999 Nov 19; 274(47):33419-25.
    View in: PubMed
    Score: 0.132
  25. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol. 1999 Jul 01; 163(1):1-5.
    View in: PubMed
    Score: 0.129
  26. Heine H, Kirschning CJ, Lien E, Monks BG, Rothe M, Golenbock DT. Cutting edge: cells that carry A null allele for toll-like receptor 2 are capable of responding to endotoxin. J Immunol. 1999 Jun 15; 162(12):6971-5.
    View in: PubMed
    Score: 0.129
  27. Ingalls RR, Monks BG, Savedra R, Christ WJ, Delude RL, Medvedev AE, Espevik T, Golenbock DT. CD11/CD18 and CD14 share a common lipid A signaling pathway. J Immunol. 1998 Nov 15; 161(10):5413-20.
    View in: PubMed
    Score: 0.123
  28. Delude RL, Yoshimura A, Ingalls RR, Golenbock DT. Construction of a lipopolysaccharide reporter cell line and its use in identifying mutants defective in endotoxin, but not TNF-alpha, signal transduction. J Immunol. 1998 Sep 15; 161(6):3001-9.
    View in: PubMed
    Score: 0.122
  29. Fenton MJ, Golenbock DT. LPS-binding proteins and receptors. J Leukoc Biol. 1998 Jul; 64(1):25-32.
    View in: PubMed
    Score: 0.120
  30. Wurfel MM, Monks BG, Ingalls RR, Dedrick RL, Delude R, Zhou D, Lamping N, Schumann RR, Thieringer R, Fenton MJ, Wright SD, Golenbock D. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med. 1997 Dec 15; 186(12):2051-6.
    View in: PubMed
    Score: 0.116
  31. N? Cheallaigh C, Sheedy FJ, Harris J, Mu?oz-Wolf N, Lee J, West K, McDermott EP, Smyth A, Gleeson LE, Coleman M, Martinez N, Hearnden CH, Tynan GA, Carroll EC, Jones SA, Corr SC, Bernard NJ, Hughes MM, Corcoran SE, O'Sullivan M, Fallon CM, Kornfeld H, Golenbock D, Gordon SV, O'Neill LA, Lavelle EC, Keane J. A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling. Immunity. 2016 Feb 16; 44(2):368-79.
    View in: PubMed
    Score: 0.102
  32. Lynn WA, Liu Y, Golenbock DT. Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide. Infect Immun. 1993 Oct; 61(10):4452-61.
    View in: PubMed
    Score: 0.087
  33. Andrade WA, Souza Mdo C, Ramos-Martinez E, Nagpal K, Dutra MS, Melo MB, Bartholomeu DC, Ghosh S, Golenbock DT, Gazzinelli RT. Combined action of nucleic acid-sensing Toll-like receptors and TLR11/TLR12 heterodimers imparts resistance to Toxoplasma gondii in mice. Cell Host Microbe. 2013 Jan 16; 13(1):42-53.
    View in: PubMed
    Score: 0.082
  34. Lehmann SM, Kr?ger C, Park B, Derkow K, Rosenberger K, Baumgart J, Trimbuch T, Eom G, Hinz M, Kaul D, Habbel P, K?lin R, Franzoni E, Rybak A, Nguyen D, Veh R, Ninnemann O, Peters O, Nitsch R, Heppner FL, Golenbock D, Schott E, Ploegh HL, Wulczyn FG, Lehnardt S. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci. 2012 Jun; 15(6):827-35.
    View in: PubMed
    Score: 0.079
  35. Caetano BC, Carmo BB, Melo MB, Cerny A, dos Santos SL, Bartholomeu DC, Golenbock DT, Gazzinelli RT. Requirement of UNC93B1 reveals a critical role for TLR7 in host resistance to primary infection with Trypanosoma cruzi. J Immunol. 2011 Aug 15; 187(4):1903-11.
    View in: PubMed
    Score: 0.074
  36. Lysakova-Devine T, Keogh B, Harrington B, Nagpal K, Halle A, Golenbock DT, Monie T, Bowie AG. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J Immunol. 2010 Oct 01; 185(7):4261-71.
    View in: PubMed
    Score: 0.070
  37. Kenny EF, Talbot S, Gong M, Golenbock DT, Bryant CE, O'Neill LA. MyD88 adaptor-like is not essential for TLR2 signaling and inhibits signaling by TLR3. J Immunol. 2009 Sep 15; 183(6):3642-51.
    View in: PubMed
    Score: 0.065
  38. Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, Mansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem. 2009 Sep 04; 284(36):24192-203.
    View in: PubMed
    Score: 0.065
  39. Santos-Sierra S, Deshmukh SD, Kalnitski J, K?enzi P, Wymann MP, Golenbock DT, Henneke P. Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. EMBO J. 2009 Jul 22; 28(14):2018-27.
    View in: PubMed
    Score: 0.064
  40. Miggin SM, P?lsson-McDermott E, Dunne A, Jefferies C, Pinteaux E, Banahan K, Murphy C, Moynagh P, Yamamoto M, Akira S, Rothwell N, Golenbock D, Fitzgerald KA, O'Neill LA. NF-kappaB activation by the Toll-IL-1 receptor domain protein MyD88 adapter-like is regulated by caspase-1. Proc Natl Acad Sci U S A. 2007 Feb 27; 104(9):3372-7.
    View in: PubMed
    Score: 0.055
  41. Knapp S, Florquin S, Golenbock DT, van der Poll T. Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol. 2006 Mar 01; 176(5):3189-95.
    View in: PubMed
    Score: 0.051
  42. Branger J, Leemans JC, Florquin S, Speelman P, Golenbock DT, van der Poll T. Lipopolysaccharide binding protein-deficient mice have a normal defense against pulmonary mycobacterial infection. Clin Immunol. 2005 Aug; 116(2):174-81.
    View in: PubMed
    Score: 0.049
  43. Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M, Takeuchi O, M?ller A, Poyart C, Akira S, Berner R, Teti G, Geyer A, Hartung T, Trieu-Cuot P, Kasper DL, Golenbock DT. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol. 2005 May 15; 174(10):6449-55.
    View in: PubMed
    Score: 0.048
  44. Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Heart Circ Physiol. 2005 Sep; 289(3):H1069-76.
    View in: PubMed
    Score: 0.048
  45. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 2005 Jun; 6(6):571-8.
    View in: PubMed
    Score: 0.048
  46. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005 Feb; 115(2):407-17.
    View in: PubMed
    Score: 0.047
  47. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. J Endotoxin Res. 2005; 11(6):363-8.
    View in: PubMed
    Score: 0.047
  48. Oliveira AC, Peixoto JR, de Arruda LB, Campos MA, Gazzinelli RT, Golenbock DT, Akira S, Previato JO, Mendon?a-Previato L, Nobrega A, Bellio M. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol. 2004 Nov 01; 173(9):5688-96.
    View in: PubMed
    Score: 0.047
  49. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology. 2004 Nov; 127(5):1513-24.
    View in: PubMed
    Score: 0.047
  50. Branger J, Florquin S, Knapp S, Leemans JC, Pater JM, Speelman P, Golenbock DT, van der Poll T. LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia. Int Immunol. 2004 Nov; 16(11):1605-11.
    View in: PubMed
    Score: 0.046
  51. Wieland CW, Knapp S, Florquin S, de Vos AF, Takeda K, Akira S, Golenbock DT, Verbon A, van der Poll T. Non-mannose-capped lipoarabinomannan induces lung inflammation via toll-like receptor 2. Am J Respir Crit Care Med. 2004 Dec 15; 170(12):1367-74.
    View in: PubMed
    Score: 0.046
  52. Darrah PA, Monaco MC, Jain S, Hondalus MK, Golenbock DT, Mosser DM. Innate immune responses to Rhodococcus equi. J Immunol. 2004 Aug 01; 173(3):1914-24.
    View in: PubMed
    Score: 0.046
  53. Mancuso G, Midiri A, Beninati C, Biondo C, Galbo R, Akira S, Henneke P, Golenbock D, Teti G. Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease. J Immunol. 2004 May 15; 172(10):6324-9.
    View in: PubMed
    Score: 0.045
  54. Liberati NT, Fitzgerald KA, Kim DH, Feinbaum R, Golenbock DT, Ausubel FM. Requirement for a conserved Toll/interleukin-1 resistance domain protein in the Caenorhabditis elegans immune response. Proc Natl Acad Sci U S A. 2004 Apr 27; 101(17):6593-8.
    View in: PubMed
    Score: 0.045
  55. Okusawa T, Fujita M, Nakamura J, Into T, Yasuda M, Yoshimura A, Hara Y, Hasebe A, Golenbock DT, Morita M, Kuroki Y, Ogawa T, Shibata K. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun. 2004 Mar; 72(3):1657-65.
    View in: PubMed
    Score: 0.045
  56. Latz E, Franko J, Golenbock DT, Schreiber JR. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol. 2004 Feb 15; 172(4):2431-8.
    View in: PubMed
    Score: 0.044
  57. Finberg RW, Re F, Popova L, Golenbock DT, Kurt-Jones EA. Cell activation by Toll-like receptors: role of LBP and CD14. J Endotoxin Res. 2004; 10(6):413-8.
    View in: PubMed
    Score: 0.044
  58. Knapp S, de Vos AF, Florquin S, Golenbock DT, van der Poll T. Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice. Infect Immun. 2003 Dec; 71(12):6747-53.
    View in: PubMed
    Score: 0.044
  59. Sandor F, Latz E, Re F, Mandell L, Repik G, Golenbock DT, Espevik T, Kurt-Jones EA, Finberg RW. Importance of extra- and intracellular domains of TLR1 and TLR2 in NFkappa B signaling. J Cell Biol. 2003 Sep 15; 162(6):1099-110.
    View in: PubMed
    Score: 0.043
  60. Huang LY, Aliberti J, Leifer CA, Segal DM, Sher A, Golenbock DT, Golding B. Heat-killed Brucella abortus induces TNF and IL-12p40 by distinct MyD88-dependent pathways: TNF, unlike IL-12p40 secretion, is Toll-like receptor 2 dependent. J Immunol. 2003 Aug 01; 171(3):1441-6.
    View in: PubMed
    Score: 0.043
  61. Sau K, Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem. 2003 Sep 26; 278(39):37561-8.
    View in: PubMed
    Score: 0.043
  62. Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003 Apr; 77(8):4588-96.
    View in: PubMed
    Score: 0.042
  63. Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol. 2002 Nov 01; 169(9):5209-16.
    View in: PubMed
    Score: 0.041
  64. Yang KK, Dorner BG, Merkel U, Ryffel B, Sch?tt C, Golenbock D, Freeman MW, Jack RS. Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J Immunol. 2002 Oct 15; 169(8):4475-80.
    View in: PubMed
    Score: 0.040
  65. Henneke P, Takeuchi O, Malley R, Lien E, Ingalls RR, Freeman MW, Mayadas T, Nizet V, Akira S, Kasper DL, Golenbock DT. Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. J Immunol. 2002 Oct 01; 169(7):3970-7.
    View in: PubMed
    Score: 0.040
  66. van der Kleij D, Latz E, Brouwers JF, Kruize YC, Schmitz M, Kurt-Jones EA, Espevik T, de Jong EC, Kapsenberg ML, Golenbock DT, Tielens AG, Yazdanbakhsh M. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem. 2002 Dec 13; 277(50):48122-9.
    View in: PubMed
    Score: 0.040
  67. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem. 2002 Dec 06; 277(49):47834-43.
    View in: PubMed
    Score: 0.040
  68. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem. 2002 Oct 18; 277(42):39320-6.
    View in: PubMed
    Score: 0.040
  69. Flo TH, Ryan L, Latz E, Takeuchi O, Monks BG, Lien E, Halaas ?, Akira S, Skj?k-Braek G, Golenbock DT, Espevik T. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem. 2002 Sep 20; 277(38):35489-95.
    View in: PubMed
    Score: 0.040
  70. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol. 2002 Jun 15; 168(12):5989-92.
    View in: PubMed
    Score: 0.040
  71. Ellingsen E, Morath S, Flo T, Schromm A, Hartung T, Thiemermann C, Espevik T, Golenbock D, Foster D, Solberg R, Aasen A, Wang J. Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med Sci Monit. 2002 May; 8(5):BR149-56.
    View in: PubMed
    Score: 0.039
  72. Massari P, Henneke P, Ho Y, Latz E, Golenbock DT, Wetzler LM. Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol. 2002 Feb 15; 168(4):1533-7.
    View in: PubMed
    Score: 0.039
  73. Yoshimura A, Kaneko T, Kato Y, Golenbock DT, Hara Y. Lipopolysaccharides from periodontopathic bacteria Porphyromonas gingivalis and Capnocytophaga ochracea are antagonists for human toll-like receptor 4. Infect Immun. 2002 Jan; 70(1):218-25.
    View in: PubMed
    Score: 0.038
  74. Medvedev AE, Henneke P, Schromm A, Lien E, Ingalls R, Fenton MJ, Golenbock DT, Vogel SN. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol. 2001 Aug 15; 167(4):2257-67.
    View in: PubMed
    Score: 0.037
  75. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res. 2001 Aug 03; 89(3):244-50.
    View in: PubMed
    Score: 0.037
  76. Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT, Boom WH, Harding CV. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J Immunol. 2001 Jul 15; 167(2):910-8.
    View in: PubMed
    Score: 0.037
  77. Campos MA, Almeida IC, Takeuchi O, Akira S, Valente EP, Proc?pio DO, Travassos LR, Smith JA, Golenbock DT, Gazzinelli RT. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol. 2001 Jul 01; 167(1):416-23.
    View in: PubMed
    Score: 0.037
  78. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001 Apr 01; 166(7):4620-6.
    View in: PubMed
    Score: 0.036
  79. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, Golenbock DT, Vogel SN, Fenton MJ. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol. 2001 Mar 15; 166(6):4074-82.
    View in: PubMed
    Score: 0.036
  80. Bernheiden M, Heinrich JM, Minigo G, Sch?tt C, Stelter F, Freeman M, Golenbock D, Jack RS. LBP, CD14, TLR4 and the murine innate immune response to a peritoneal Salmonella infection. J Endotoxin Res. 2001; 7(6):447-50.
    View in: PubMed
    Score: 0.036
  81. Means TK, Golenbock DT, Fenton MJ. Structure and function of Toll-like receptor proteins. Life Sci. 2000 Dec 08; 68(3):241-58.
    View in: PubMed
    Score: 0.036
  82. Flo TH, Ryan L, Kilaas L, Skj?k-Braek G, Ingalls RR, Sundan A, Golenbock DT, Espevik T. Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers. Infect Immun. 2000 Dec; 68(12):6770-6.
    View in: PubMed
    Score: 0.036
  83. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000 Nov; 1(5):398-401.
    View in: PubMed
    Score: 0.035
  84. Means TK, Golenbock DT, Fenton MJ. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 2000 Sep; 11(3):219-32.
    View in: PubMed
    Score: 0.035
  85. Flo TH, Halaas O, Lien E, Ryan L, Teti G, Golenbock DT, Sundan A, Espevik T. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol. 2000 Feb 15; 164(4):2064-9.
    View in: PubMed
    Score: 0.034
  86. Yoshimura A, Takada H, Kaneko T, Kato I, Golenbock D, Hara Y. Structural requirements of muramylpeptides for induction of Toll-like receptor 2-mediated NF-kappaB activation in CHO cells. J Endotoxin Res. 2000; 6(5):407-10.
    View in: PubMed
    Score: 0.033
  87. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton MJ. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol. 1999 Dec 15; 163(12):6748-55.
    View in: PubMed
    Score: 0.033
  88. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol. 1999 Oct 01; 163(7):3920-7.
    View in: PubMed
    Score: 0.033
  89. Ingalls RR, Heine H, Lien E, Yoshimura A, Golenbock D. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect Dis Clin North Am. 1999 Jun; 13(2):341-53, vii.
    View in: PubMed
    Score: 0.032
  90. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999 Apr 16; 274(16):10689-92.
    View in: PubMed
    Score: 0.032
  91. Dutra FF, Alves LS, Rodrigues D, Fernandez PL, de Oliveira RB, Golenbock DT, Zamboni DS, Bozza MT. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci U S A. 2014 Sep 30; 111(39):E4110-8.
    View in: PubMed
    Score: 0.023
  92. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, Lambe EM, Creagh EM, Golenbock DT, Tschopp J, Kornfeld H, Fitzgerald KA, Lavelle EC. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem. 2011 Mar 18; 286(11):9587-97.
    View in: PubMed
    Score: 0.018
  93. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010 Nov 03; 12(5):467-82.
    View in: PubMed
    Score: 0.018
  94. He Y, Barker SJ, MacDonald AJ, Yu Y, Cao L, Li J, Parhar R, Heck S, Hartmann S, Golenbock DT, Jiang S, Libri NA, Semper AE, Rosenberg WM, Lustigman S. Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells. J Immunol. 2009 Apr 01; 182(7):4005-16.
    View in: PubMed
    Score: 0.016
  95. Boon Hinckley M, Reynolds CM, Ribeiro AA, McGrath SC, Cotter RJ, Lauw FN, Golenbock DT, Raetz CR. A Leptospira interrogans enzyme with similarity to yeast Ste14p that methylates the 1-phosphate group of lipid A. J Biol Chem. 2005 Aug 26; 280(34):30214-24.
    View in: PubMed
    Score: 0.012
  96. Zhou S, Kurt-Jones EA, Mandell L, Cerny A, Chan M, Golenbock DT, Finberg RW. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur J Immunol. 2005 Mar; 35(3):822-30.
    View in: PubMed
    Score: 0.012
  97. Hasebe A, Yoshimura A, Into T, Kataoka H, Tanaka S, Arakawa S, Ishikura H, Golenbock DT, Sugaya T, Tsuchida N, Kawanami M, Hara Y, Shibata K. Biological activities of Bacteroides forsythus lipoproteins and their possible pathological roles in periodontal disease. Infect Immun. 2004 Mar; 72(3):1318-25.
    View in: PubMed
    Score: 0.011
  98. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003 May; 4(5):491-6.
    View in: PubMed
    Score: 0.011
  99. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci. 2002 Jun 15; 115(Pt 12):2603-11.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.